Sign in or create an account to add this stock to your watchlist.
About Celyad (NASDAQ:CYAD)
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYAD
CUSIPN/A
Phone321-039-4100
Debt
Debt-to-Equity Ratio0.02
Current Ratio4.58
Quick Ratio4.58
Price-To-Earnings
Trailing P/E Ratio-7.60
Forward P/E Ratio-5.99
P/E GrowthN/A
Sales & Book Value
Annual Sales$4 million
Price / Sales66.38
Cash FlowN/A
Price / CashN/A
Book Value$5.44 per share
Price / Book4.94
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees88
Outstanding Shares9,870,000
Celyad (NASDAQ:CYAD) Frequently Asked Questions
What is Celyad's stock symbol?
Celyad trades on the NASDAQ under the ticker symbol "CYAD."
What price target have analysts set for CYAD?
1 brokers have issued 1-year target prices for Celyad's stock. Their predictions range from $74.00 to $74.00. On average, they expect Celyad's share price to reach $74.00 in the next year. View Analyst Ratings for Celyad.
Who are some of Celyad's key competitors?
Some companies that are related to Celyad include TG Therapeutics (TGTX), Lexicon Pharmaceuticals (LXRX), Mirati Therapeutics (MRTX), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Zai Lab (ZLAB), Endocyte (ECYT), Karyopharm Therapeutics (KPTI), Omeros (OMER), Eagle Pharmaceuticals (EGRX), CytomX Therapeutics (CTMX), Amarin (AMRN), MacroGenics (MGNX), OptiNose (OPTN) and UroGen Pharma (URGN).
Who are Celyad's key executives?
Celyad's management team includes the folowing people:
- Mr. Michel E. Lussier MS BME, MBA, Co-Founder & Chairman (Age 62)
- Dr. Christian Homsy M.D., MBA, CEO & Exec. Director (Age 60)
- Mr. Patrick Jeanmart, Chief Financial Officer & Investor Relations (Age 46)
- Dr. Jean-Pierre Latere, Chief Operating Officer (Age 43)
- Mr. Philippe Dechamps, Chief Legal Officer (Age 48)
When did Celyad IPO?
(CYAD) raised $99 million in an initial public offering on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.
Has Celyad been receiving favorable news coverage?
News headlines about CYAD stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celyad earned a news impact score of 0.18 on Accern's scale. They also gave media headlines about the company an impact score of 50.21 out of 100, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days.
Who are Celyad's major shareholders?
Celyad's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (4.31%) and Jane Street Group LLC (0.17%). View Institutional Ownership Trends for Celyad.
Which institutional investors are selling Celyad stock?
Which institutional investors are buying Celyad stock?
How do I buy shares of Celyad?
Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celyad's stock price today?
One share of CYAD stock can currently be purchased for approximately $26.90.
How big of a company is Celyad?
Celyad has a market capitalization of $265.56 million and generates $4 million in revenue each year. The company earns $-63,740,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. Celyad employs 88 workers across the globe.
How can I contact Celyad?
Celyad's mailing address is Rue Edouard Belin 2, Mont-Saint-Guibert C9, 1435. The company can be reached via phone at 321-039-4100.
MarketBeat Community Rating for Celyad (CYAD)
MarketBeat's community ratings are surveys of what our community members think about Celyad and other stocks. Vote "Outperform" if you believe CYAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Celyad (NASDAQ:CYAD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Celyad in the last 12 months. Their average twelve-month price target is $74.00, suggesting that the stock has a possible upside of 175.09%. The high price target for CYAD is $74.00 and the low price target for CYAD is $74.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $74.00 | $74.00 | $74.00 | $74.00 |
| Price Target Upside: | 175.09% upside | 20.92% upside | 20.92% upside | 20.92% upside |
Celyad (NASDAQ:CYAD) Consensus Price Target History
Celyad (NASDAQ:CYAD) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/9/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $74.00 | N/A |  |
| 7/5/2016 | UBS | Downgrade | Buy ➝ Neutral | $79.00 ➝ $27.00 | N/A | |
(Data available from 5/20/2016 forward)
Celyad (NASDAQ:CYAD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Celyad (NASDAQ CYAD) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 4.54%
Celyad (NASDAQ CYAD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Celyad (NASDAQ CYAD) News Headlines
| Source: |
|
Celyad (NASDAQ:CYAD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Celyad (NASDAQ:CYAD) Income Statement, Balance Sheet and Cash Flow Statement
Celyad (NASDAQ CYAD) Stock Chart for Sunday, May, 20, 2018
Loading chart…
